Andy G. Hinson directs the clinical and regulatory activities at Symphony Medical. Andy has 15 years of bio-pharmaceutical industry experience and 20 years of experience spanning clinical and R&D assignments in the cardiovascular arena. Prior to joining Symphony Medical in November 2004, Andy was Senior Director of Research & Development at AnGes Inc, a successful Japanese biotechnology start-up that is developing novel gene based approaches for the treatment of cardiovascular disease. During Andy's tenure at AnGes, the company successfully filed IND's in the US and Japan and advanced combinations of device and biologics into early and late stage clinical programs. These clinical development programs included the first human studies ever performed for the gene transfer of hepatocyte growth factor and NFKB (nuclear factor kappa B) decoy, as the company transitioned from a start-up venture to a publicly traded company on the Tokyo Stock Exchange of nearly 100 employees. Before that, Andy was a Senior Manager in the Medical Affairs & Clinical Development Cardiovascular Division at Procter & Gamble Pharmaceutical. Andy's long tenure at P&GP included a variety of research and development responsibilities spanning arrhythmia, heart failure, hypertension and myocardial injury programs. Andy's early career began as a cardiovascular technologist and applications consultant to the medical device industry.